Back to Search Start Over

Central serous chorioretinopathy with and without steroids: A multicenter survey.

Authors :
Araki T
Ishikawa H
Iwahashi C
Niki M
Mitamura Y
Sugimoto M
Kondo M
Kinoshita T
Nishi T
Ueda T
Kato A
Yasukawa T
Takamura Y
Gomi F
Source :
PloS one [PLoS One] 2019 Feb 28; Vol. 14 (2), pp. e0213110. Date of Electronic Publication: 2019 Feb 28 (Print Publication: 2019).
Publication Year :
2019

Abstract

We investigated the rates of the use of steroids in Japanese central serous chorioretinopathy (CSC) cases and differences in the characteristics of CSC with and without steroids. A total of 538 eyes of 477 patients diagnosed with CSC, with 3 months or more of follow-up between April 2013 and June 2017 at 8 institutions. Patients with CSC with more than 3 months of follow-up were identified by OCT and fluorescein angiography at 8 institutions. Data collected included patient demographics, history of corticosteroid medication and smoking, spherical errors, findings of angiography, subfoveal choroidal thickness, and changes through the follow-up period. Differences in these findings were analyzed in cases with and without corticosteroid treatment. Among the 477 patients (344 men,133 women), 74 (15.5%) (39 men, 35 women) underwent current or prior steroid treatment. Cases with steroids were higher age (p = 0.0403) and showed no male prevalence, more bilateral involvement (p < 0.0001), and the affected eyes had multiple pigment epithelial detachment (p <0.0001), more fluorescein leakage sites (p < 0.0001), greater choroidal thickness (p = 0.0287) and a higher recurrence rate (p = 0.0412). Steroids can cause severer CSC through an effect on choroidal vessels and an impairment of retinal pigment epithelium.<br />Competing Interests: The authors have declared that no competing interests exist.

Details

Language :
English
ISSN :
1932-6203
Volume :
14
Issue :
2
Database :
MEDLINE
Journal :
PloS one
Publication Type :
Academic Journal
Accession number :
30818363
Full Text :
https://doi.org/10.1371/journal.pone.0213110